https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-01 / J. Immunother. 2008 May;31(4):345-58
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-01 / J. Immunother. 2008 May;31(4):345-582008-05-01 00:00:002019-02-15 09:19:30Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-01 / J. Immunother. 2008 May;31(4):402-12
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-01 / J. Immunother. 2008 May;31(4):402-122008-05-01 00:00:002019-02-15 09:19:31Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-01 / Rev Recent Clin Trials 2008 May;3(2):121-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-01 / Rev Recent Clin Trials 2008 May;3(2):121-52008-05-01 00:00:002019-02-15 09:23:43Immunotherapy of pancreatic carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-24 / Vaccine 2008 Jun;26(27-28):3540-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-24 / Vaccine 2008 Jun;26(27-28):3540-92008-04-24 00:00:002019-02-15 08:49:58Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-21 / J. Leukoc. Biol. 2008 Jul;84(1):319-25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-21 / J. Leukoc. Biol. 2008 Jul;84(1):319-252008-04-21 00:00:002019-02-15 08:37:26Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-15 / Int. J. Cancer 2008 Apr;122(8):1794-802
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-15 / Int. J. Cancer 2008 Apr;122(8):1794-8022008-04-15 00:00:002019-02-15 08:59:45Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-09 / Trends Mol Med 2008 May;14(5):228-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-09 / Trends Mol Med 2008 May;14(5):228-352008-04-09 00:00:002019-02-15 08:46:53Cell- and peptide-based immunotherapeutic approaches for glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-01 / J. Clin. Invest. 2008 Apr;118(4):1427-36
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-01 / J. Clin. Invest. 2008 Apr;118(4):1427-362008-04-01 00:00:002008-04-01 00:00:00The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-01 / Immunol. Rev. 2008 Apr;222:256-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-01 / Immunol. Rev. 2008 Apr;222:256-762008-04-01 00:00:002008-04-01 00:00:00Reengineering dendritic cell-based anti-cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-01 / Am. J. Hematol. 2008 Apr;83(4):315-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-01 / Am. J. Hematol. 2008 Apr;83(4):315-72008-04-01 00:00:002019-02-15 08:32:32Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia
